Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab

BACKGROUND: Studies assessing the efficacy of therapies for neovascular age-related macular degeneration (nvAMD) have demonstrated that aflibercept may have a longer treatment interval than its less-expensive alternative, bevacizumab. However, whether this benefit justifies the additional cost of af...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xuan, Sanchez, Jaron Castillo, Patel, Tapan P., Yang, Zhiyong, Guo, Chuanyu, Malik, Danyal, Sopeyin, Anuoluwapo, Montaner, Silvia, Sodhi, Akrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843049/
https://www.ncbi.nlm.nih.gov/pubmed/36413411
http://dx.doi.org/10.1172/JCI159125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843049/
https://www.ncbi.nlm.nih.gov/pubmed/36413411
http://dx.doi.org/10.1172/JCI159125

Ejemplares similares